What are the subtypes of acute heart failure and the recommended initial treatment for each?

Acute Heart Failure Subtypes and Initial Treatment

Acute heart failure should be classified into distinct clinical phenotypes based on blood pressure and perfusion status, with treatment tailored accordingly: hypertensive/wet phenotype receives IV vasodilators plus diuretics; normotensive/congested phenotype receives IV loop diuretics; hypotensive/hypoperfused phenotype receives inotropes; and cardiogenic shock requires vasopressors plus mechanical support. 1

Clinical Phenotypes of Acute Heart Failure

The most clinically relevant classification system divides acute heart failure into phenotypes based on hemodynamic presentation 2, 1:

1. Wet Hypertensive Phenotype

• Clinical presentation: Systolic BP >140 mmHg, pulmonary congestion, volume overload
• Pathophysiology: Excessive vasoconstriction with preserved cardiac output, rapid fluid redistribution
• Initial treatment priority:
  • IV vasodilators as first-line therapy (nitroglycerin or nitroprusside) to reduce afterload and preload 1
  • Loop diuretics (furosemide 20-40 mg IV bolus if diuretic-naive, or equivalent to home dose if on chronic therapy) 1
  • Consider acetazolamide 500 mg IV plus loop diuretics for superior decongestion 2

Critical point: This phenotype has the best prognosis and widest therapeutic window due to elevated BP providing hemodynamic reserve 2.

2. De Novo Heart Failure Phenotype

• Clinical presentation: First presentation of heart failure, no prior diagnosis
• Treatment approach:
  • Immediate decongestion with IV loop diuretics (furosemide 20-40 mg IV) 1
  • Rapid introduction of all 4 pillars of guideline-directed medical therapy (GDMT) before discharge: ACE-I/ARB or ARNI, beta-blocker, mineralocorticoid receptor antagonist, SGLT2 inhibitor 2
  • Personalize the order of GDMT introduction based on blood pressure, heart rate, renal function, and potassium levels 2

3. Worsening Heart Failure Phenotype

• Clinical presentation: Decompensation of chronic heart failure despite oral therapy
• Significance: Marker of poor prognosis requiring aggressive intervention 2
• Treatment strategy:
  • IV loop diuretics at doses at least equivalent to oral dose (typically higher) 1
  • Optimize existing GDMT dosing
  • Consider second-line therapies (vericiguat, hydralazine-nitrate combination)
  • Evaluate for advanced heart failure therapies or goals of care discussion 2

4. Cardiorenal Phenotype

• Clinical presentation: Heart failure with significant renal dysfunction
• Key principle: Renal function typically improves with decongestion, not worsens 2
• Treatment approach:
  • Aggressive diuresis despite rising creatinine (if patient remains volume overloaded)
  • Combination diuretics: loop diuretic plus thiazide or spironolactone for diuretic resistance 1, 3
  • Monitor urine output, daily weights, and natriuresis (not just creatinine)
  • Correct volume assessment is critical—avoid premature diuretic discontinuation

5. Hypotensive/Hypoperfused Phenotype (Including Cardiogenic Shock)

• Clinical presentation: SBP <90 mmHg with signs of end-organ hypoperfusion (cold extremities, altered mental status, oliguria, elevated lactate)
• Treatment hierarchy:
  • Inotropes (dobutamine, levosimendan, or milrinone) for SBP <90 mmHg with hypoperfusion 1
  • Vasopressors (norepinephrine preferred) if persistent shock despite inotropes 1
  • Avoid diuretics until perfusion restored—patients with hypotension, severe hyponatremia, or acidosis unlikely to respond 3
  • Immediate transfer to tertiary center with mechanical circulatory support capability 1
  • Consider mechanical support (IABP, Impella, VA-ECMO) early in refractory shock

Safety warning: Inotropes and vasopressors cause arrhythmias and myocardial ischemia—continuous ECG monitoring mandatory 1.

6. Frail Heart Failure Phenotype

• Clinical presentation: Elderly, multiple comorbidities, functional limitations
• Treatment modifications:
  • Careful drug titration with lower starting doses
  • Cardiac rehabilitation programs strongly recommended 2
  • Avoid iatrogenic harm (unnecessary urinary catheters, prolonged boarding) 4

Universal Initial Management Principles

Respiratory Support

• Oxygen therapy: Target SpO2 >90%, avoid hyperoxia 1
• Non-invasive ventilation (CPAP or BiPAP): Start immediately for respiratory distress with pulmonary edema—reduces intubation rates and may reduce mortality 1, 5
• Intubation reserved for progressive hypoxia despite NIV or respiratory muscle fatigue 3

Diuretic Dosing Algorithm

• Diuretic-naive patients: Furosemide 20-40 mg IV bolus 1
• Chronic diuretic users: IV dose ≥ oral home dose 1
• Administration: Bolus or continuous infusion equally effective—adjust based on urine output 1
• Diuretic resistance: Add thiazide (hydrochlorothiazide 25 mg) or spironolactone 25-50 mg 3
• Monitor: Urine output hourly, daily weights, electrolytes, renal function 1

Medications to Avoid or Use Cautiously

• Morphine: Associated with increased mechanical ventilation, ICU admission, and death in registry data—not routinely recommended 5
• Inotropes in normotensive patients: Contraindicated due to increased mortality risk 1
• Beta-blockers: Continue in stable patients; reduce or hold temporarily if hypotensive or severely decompensated 1

Common Pitfalls

1. Underdosing diuretics in chronic users: Must match or exceed home oral dose when converting to IV 1
2. Stopping diuretics prematurely for rising creatinine: In cardiorenal phenotype, continue diuresis if patient remains congested—renal function improves with decongestion 2
3. Using inotropes in hypertensive acute heart failure: Increases mortality—use vasodilators instead 1
4. Delaying GDMT initiation: Start before discharge, not at follow-up—improves outcomes 2, 4
5. Inadequate decongestion assessment: Residual congestion at discharge predicts readmission—ensure complete decongestion 6

Risk Stratification and Disposition

Use validated tools (EHMRG, MEESSI-AHF scores) to guide admission decisions and intensity of monitoring 4. Patients with hypotension, elevated troponin, renal dysfunction, or hyponatremia require intensive monitoring 7.